Allen Investment Management’s Biogen BIIB Stock Holding History

Allen Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,523	Closed	-$605K	–	236
2021 Q4	$605K	Buy	+2,523	New	+$649K	0.01%	173

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Allen Investment Management's BIIB Position: Q1 2022 in Review

Allen Investment Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 2,523 shares — an estimated $605K sold.

Allen Investment Management first reported a position in BIIB in Q4 2021 and held it in 1 quarter. The position peaked at $605K in Q4 2021. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

Allen Investment Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
Allen Investment Management sold 2,523 Biogen shares in Q1 2022, an estimated $605K.
Allen Investment Management first reported a position in Biogen in Q4 2021 and held it in 1 quarter.
Allen Investment Management's Biogen position peaked at $605K in Q4 2021.
951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Allen Investment Management's 13F filing for Q1 2022, filed 5 May 2022.